Stoke Therapeutics

Yahoo Finance • 6 hours ago

These Growth Stocks Form Classic Cup Bases. Here's Where To Buy.

Two eyedrops stocks are forming cup bases on their charts and one has earnings coming up. A data center play is in a cup base buy zone. Continue Reading... Full story

Yahoo Finance • 5 days ago

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million

On February 17, 2026, Redmile Group disclosed a buy of 4,415,514 Nurix Therapeutics(NASDAQ:NRIX) shares, an estimated $63.43 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commissio... Full story

Yahoo Finance • 5 days ago

Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%

On February 17, 2026, Redmile Group disclosed a buy of 695,000 shares of Immunome(NASDAQ:IMNM), an estimated $12.20 million trade based on quarterly average pricing. What happened According to a February 17, 2026, SEC filing, Redmile Gro... Full story

Yahoo Finance • 5 days ago

Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year

Redmile Group disclosed a significant reduction in its Zymeworks(NASDAQ:ZYME) position in a February 17, 2026, SEC filing, selling an estimated $70.10 million in shares based on quarterly average pricing. What happened According to a Feb... Full story

Yahoo Finance • 5 days ago

Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025

Redmile Group reported a purchase of 16,317 shares of Krystal Biotech(NASDAQ:KRYS) in its February 17, 2026, SEC filing, with the estimated transaction value at $3.43 million based on quarterly average pricing. What happened According to... Full story

Yahoo Finance • 5 days ago

Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26%

Redmile Group disclosed a buy of 1,316,390 shares of Scholar Rock Holding Corporation(NASDAQ:SRRK) in a February 17, 2026, SEC filing, with the estimated transaction value at $49.37 million based on quarterly average pricing. What happene... Full story

Yahoo Finance • 16 days ago

High Growth Tech Stocks In The US February 2026

As February 2026 begins, the U.S. stock market has seen a robust start with major indices like the Dow Jones Industrial Average and S&P 500 showing significant gains, reflecting positive investor sentiment despite recent economic uncertain... Full story

Yahoo Finance • 3 months ago

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs)demonstrate durable seizure reductions, including increases in seizure-free days, in addition to improvement... Full story

Yahoo Finance • 3 months ago

Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

CAMBRIDGE, Mass and BEDFORD, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s pote... Full story

Yahoo Finance • 3 months ago

A Look at Biogen (BIIB) Valuation Following New Dravet Syndrome Study Results

Biogen (BIIB) and Stoke Therapeutics just published final results from the two-year BUTTERFLY study. The data highlights that neurodevelopment in Dravet syndrome patients plateaus at around age two, despite currently available therapies.... Full story

Yahoo Finance • 3 months ago

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative to children with typical development –... Full story

Yahoo Finance • 3 months ago

Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative to children with typical development –... Full story

Yahoo Finance • 4 months ago

Implied JSMD Analyst Target Price: $92

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 5 months ago

Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal change in natural history – – Improveme... Full story

Yahoo Finance • 5 months ago

Stoke Therapeutics Names Ian Smith As CEO; Phase 3 Trial Of Zorevunersen Underway

(RTTNews) - Stoke Therapeutics, Inc. (STOK), on Monday, announced that it has appointed Ian Smith as Chief Executive Officer. Smith has served as Interim CEO since March 2025. Smith will continue to serve as a Director on the Company's Bo... Full story

Yahoo Finance • 5 months ago

7 Biotech Stocks Trading At 52-Week Highs - Can The Rally Continue?

(RTTNews) - Patience is a virtue - important in all aspects of life, and especially crucial when it comes to investing. As trading expert Steve Burns once said, "Much of our trading comes down to a battle between our patience and our impul... Full story

Yahoo Finance • 6 months ago

Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies – – Substantial increase in seizure-free days and... Full story

Yahoo Finance • 6 months ago

Stoke Therapeutics stock hits 52-week high at $18.61

Stoke Therapeutics Inc (NASDAQ:STOK). stock reached a significant milestone, hitting a 52-week high of $18.61. According to InvestingPro data, the company’s impressive momentum includes a 36.81% gain in the past week alone, with the stock... Full story

Yahoo Finance • 7 months ago

Biogen, Stoke Therapeutics Dose First Patient in Phase 3 Trial of Zorevunersen for Dravet Syndrome

Biogen (BIIB) and Stoke Therapeutics (STOK) said Monday they have dosed a first participant in a pha PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 7 months ago

Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period – – Dravet syndrome is a rare genetic disease characterized by refractory seizures and neurodevelopmental i... Full story